What's New View more articles
Boehringer Ingelheim and Enleofen Bio Ink USD 1 Billion Deal

Enleofen Bio (a spin off company of SingHealth Duke-NUS AMC) and global pharmaceutical giant, Boehringer Ingelheim, inked a USD1 billion deal to further develop therapies for multiple fibrotic human disorders, including non-alcoholic steatohepatitis (NASH) and progressive fibrosing interstitial lung diseases (PF-ILDs); bringing hope to patients with fibro-inflammatory conditions worldwide.

 

"We are very excited to engage Boehringer Ingelheim, a leading and innovative pharmaceutical company on this important phase of drug and clinical development. This marks a major biotechnology success in Singapore and we are extremely proud of the clinicians and scientists at NHCS and Duke-NUS," said Professor Stuart Cook, Tanoto Foundation Professor of Cardiovascular Medicine, Director of Duke-NUS’ Cardiovascular and Metabolic Disorders Programme, and Senior Consultant at the Department of Cardiology, NHCS.

KKH Collaborates with NUS to Develop World-First AI-Powered System to Enhance Accuracy of Spinal Anaesthesia
 
KKH Study: Rise in Number of Children Being Injured from Trampoline-Related Falls
SERI-NTU Advanced Ocular Engineering (STANCE) Lab to Develop Technologies to Better Manage Eye Diseases
 KKH Study: Pregnant Women Who Eat at Night Have Difficulties Getting Rid of Post-Pregnancy Belly 18 Months After Delivery